Dr. Qianqian Wang, MD, FRCSC

Claim this profile

Centre Hospitalier de l'Université de Montréal

Studies Glaucoma
Studies Pigmentary Glaucoma
2 reported clinical trials
3 drugs studied

Affiliated Hospitals

Image of trial facility.
Centre Hospitalier De L'Université De Montréal
Image of trial facility.
Centre Hospitalier De L'Université De Montréal (CHUM)

Clinical Trials Qianqian Wang, MD, FRCSC is currently running

Image of trial facility.

Laser Treatment

for Glaucoma Prevention in Corneal Disease

The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success. Glaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure. In order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye. The transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis. Our hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis . METHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist. Following their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.
Recruiting1 award N/A

More about Qianqian Wang, MD, FRCSC

Clinical Trial Related5 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Qianqian Wang, MD, FRCSC has experience with
  • Topical Insulin Drops
  • G-Probe Transscleral Cyclphophotocoagulation
  • Transscleral Cyclphophotocoagulation Using The Micropulse System

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Qianqian Wang, MD, FRCSC specialize in?
Qianqian Wang, MD, FRCSC focuses on Glaucoma and Pigmentary Glaucoma. In particular, much of their work with Glaucoma has involved treating patients, or patients who are undergoing treatment.
Is Qianqian Wang, MD, FRCSC currently recruiting for clinical trials?
Yes, Qianqian Wang, MD, FRCSC is currently recruiting for 1 clinical trial in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Qianqian Wang, MD, FRCSC has studied deeply?
Yes, Qianqian Wang, MD, FRCSC has studied treatments such as Topical Insulin Drops, G-Probe transscleral cyclphophotocoagulation, Transscleral cyclphophotocoagulation using the Micropulse system.
What is the best way to schedule an appointment with Qianqian Wang, MD, FRCSC?
Apply for one of the trials that Qianqian Wang, MD, FRCSC is conducting.
What is the office address of Qianqian Wang, MD, FRCSC?
The office of Qianqian Wang, MD, FRCSC is located at: Centre Hospitalier de l'Université de Montréal, Montréal, Quebec H2X 3E4 Canada. This is the address for their practice at the Centre Hospitalier de l'Université de Montréal.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.